biocon stock

Biocon subsidiary gets USFDA nod for generic drug for chronic heart failure

Biotechnology firm Biocon said its subsidiary has received approval from the US health regulator to market a generic medication to treat chronic heart failure. Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing. Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation. The medicine is also used to treat paediatric patients over the age of one year. The approval further adds to Biocon's portfolio of vertically integrated, complex drug products, the company said.

Biocon Q1 net profit up 551%, driven by gain from Eris Life partnership

Total revenue stood at Rs 4,567 crore in Q1 FY25 as against Rs 3,516 crore in Q1 FY24

Adani Ports, Zydus Life, Paytm, Zomato among 11 stocks to track on June 18

On the previous day, US markets settled higher, with Nasdaq and S&P 500 reaching record highs

Stocks to watch on June 04: DRL, Biocon, Wipro, RVNL, M&M Fin Svcs

Stocks to watch on June 04: RVNL has secured an engineering, procurement and construction order worth Rs 440 crore from South Central Railway

Biocon signs licensing, supply deal for obesity drug in South Korea

Bengaluru-based company announces 'strategic partnership' with Handok

Stocks to Watch, May 22: Apollo Tyres, Biocon, Gulf Oil, Ircon Int'l

European markets closed on a negative note, with Germany's DAX falling 0.22 per cent and the UK's FTSE dropping 0.09 per cent

RIL, Adani Ports, Vi, Biocon, CONCOR among nine stocks to track on May 17

At 6:51 AM, GIFT Nifty futures showed a rise of 26 points, trading at 22,478 levels, signaling a subdued start for the stock exchanges

Biocon receives a penalty of over Rs 3 crore in GST related issues

Biocon Ltd on Friday said it has been imposed a penalty of over Rs 3 crore over GST-related issues. The company has received an order of adjudication imposing a penalty of Rs 3,03,78,465 dated February 22, 2024, from the office of Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalore, Biocon Ltd said in a regulatory filing. The demand is related to input tax credit reporting error in GST monthly returns, denial of input tax credit on sales and promotional expenditures, valuation issue GST under corporate guarantee, and denial of exemption on export of services, it added. Biocon further said it is "in the process of taking appropriate actions, including but not limited to, filing of the necessary appeal with the appellate authority in this regard". There is no material impact on the financials, operations or other activities of the company, the filing said.

Biocon Biologics partners with Sandoz Australia to sell cancer drugs

The partnership will provide Sandoz the exclusive rights to promote, sell, and distribute biosimilar Trastuzumab and biosimilar Bevacizumab in Australia

Biocon inks pact with Sandoz for sale of 2 biosimilar products in Australia

Biocon Biologics on Friday said it has inked a five-year pact with pharmaceutical company Sandoz AG regarding the sale and distribution of two cancer treatment biosimilar products in Australia. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement. Biocon Biologics is a subsidiary of Biocon Ltd. Under the agreement, Sandoz will distribute the Biocon Biologics' brands, Ogivri (Trastuzumab) and Abevmy (Bevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin and utilised for the treatment of various cancers. "Following the recent establishment of our strategic partnership with Sandoz in Japan, our agreement with Sandoz in Australia marks another important milestone of our globa

Investing half a billion dollar in our generics business: Biocon MD & CEO

Debt-reduction plans are progressing a tad slowly, said Siddharth Mittal

Biocon considers selling generic API biz; turn into biosimilar major

The generic API business has been one of the primary businesses for Biocon, however, in recent years, the segment's contribution towards the company's consolidated financials has declined

Biocon Biologics appoints Kedar Upadhye as new chief financial officer

Current CFO, MB Chinappa will take on a strategic finance role at Biocon Group

Biocon Biologics gets positive opinion from EMA for ophthalmology product

Yesafili aims to treat various visual impairments and age-related macular degeneration

Biocon shares trim most of early gains, end flat amid profit-taking

Shares of Biocon trimmed most of their early gains and ended flat on Wednesday amid profit-taking. During the early trade, the stock climbed nearly 8 per cent after the biotechnology major's consolidated net profit increased 31 per cent for the March quarter. The stock gained 7.12 per cent to Rs 259.50 during the day on the BSE but failed to hold on to the momentum and ended flat. It settled at Rs 243 apiece, marginally up 0.31 pe cent. On the NSE, the stock settled at Rs 242.95 per share, a gain of 0.33 per cent after rallying 7.61 per cent to Rs 260.60 during the day. In volume terms, 18.97 lakh shares of the company were traded on the BSE and over 1.77 crore shares on the NSE during the day. On Tuesday, Biocon said its consolidated net profit increased 31 per cent to Rs 313 crore for the March quarter on the back of robust sales. The company had reported a net profit of Rs 239 crore in January-March 2021-22. Total revenue increased to Rs 3,929 crore in the fourth quarter as a

Nifty Pharma dips to 7-mth low; bears may gain control if breaks 52-wk low

Barring Sun Pharmaceutical Industries, which is anticipated to rally up to 10 per cent; other stocks indicate weak bias, as per technical charts

Viatris deal-related expenses drag Biocon's Q3 net into Rs 42 cr loss

This, even as revenues rise 36% and Ebitda is up 35%

MSCI revision: CG Power, Bank Baroda look bullish on charts; avoid Biocon

Biocon share may slip up to 21 per cent if breaks 52-week low

Biocon sells 9.96% stake in contract research firm Syngene via open market

Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing

Stocks to Watch: Zomato, SBI, Adani Group, Britannia, ONGC, Gland Pharma

Stocks to Watch Today: According to reports, Zomato is likely to witness a block deal on Wednesday.